TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Eligible age

18–70 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

Sponsor: Jonsson Comprehensive Cancer Center

You may qualify if…

  • ✓ Ages 18-70 years
  • ✓ One of the following:
  • ✓ Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:
  • ✓ High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc
  • ✓ Large B-cell lymphoma with a history of secondary CNS involvement
  • ✓ Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia
  • ✓ High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis
  • ✓ Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma

You may not qualify if…

  • ✕ Cord blood as donor source in alloHCT
  • ✕ New York Heart Association Class III or IV
  • ✕ Left ventricular ejection fraction \< 50%
  • ✕ Estimated glomerular filtration rate \< 30 mL/min
  • ✕ Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication
  • ✕ Acute or chronic graft-versus-host disease (GvHD) \>= stage 3 at time of enrollment
  • ✕ Received packed red blood cells (pRBC) transfusion within the past 2 weeks
  • ✕ Received platelet transfusion within the past 1 week

Where it's recruiting

California

Los Angeles · Sacramento

Oklahoma

Oklahoma City

Source: ClinicalTrials.gov · NCT05256641 · last updated 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-c · TrialPath